Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer

Lavinia Nardinocchi, Giulio Sonego, Francesca Passarelli, Simona Avitabile, Claudia Scarponi, Cristina Maria Failla, Stefano Simoni, Cristina Albanesi, Andrea Cavani

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Interleukin-17 (IL-17) and IL-22 have been reported to play critical roles in autoimmunity and inflammation but information about their role in cancer is limited. In this study, we investigated the role of IL-17 and IL-22 in the progression of human skin basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC). We found that both tumor types are infiltrated with an high number of IL-17+ and IL-22+ T lymphocytes, as demonstrated by immunohistochemistry and by FACS analysis performed on peritumoral T-cell lines isolated from skin biopsies. In vitro studies demonstrated that proliferation and migration of the BCC- and SCC-cell lines M77015 and CAL27 were increased by IL-17 and IL-22. Moreover, IL-17, alone or in combination with TNF-α, was able to induce the production of two cytokines important for tumor progression, IL-6 and IL-8, in CAL27. We also showed that IL-17 upregulated NF-κB signaling, while IL-22 activated the STAT3 pathway and the antiapoptotic AKT protein in M77015 and CAL27. Finally, in vivo experiments demonstrated that IL-17 and IL-22 enhanced tumor growth in nude mice injected with CAL27. Altogether, our findings indicate that high levels of IL-22 and IL-17 in the BCC and SCC microenvironment promote tumor progression.

Original languageEnglish
Pages (from-to)922-931
Number of pages10
JournalEuropean Journal of Immunology
Volume45
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Interleukin-17
Skin Neoplasms
Basal Cell Carcinoma
Neoplasms
Squamous Cell Carcinoma
T-Lymphocytes
Cellular Microenvironment
Cell Line
Skin
interleukin-22
Autoimmunity
Interleukin-8
Nude Mice
Interleukin-6
Immunohistochemistry
Cytokines
Inflammation
Biopsy
Growth

Keywords

  • Cancer
  • Dermatology
  • IL-17
  • IL-22
  • T cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. / Nardinocchi, Lavinia; Sonego, Giulio; Passarelli, Francesca; Avitabile, Simona; Scarponi, Claudia; Failla, Cristina Maria; Simoni, Stefano; Albanesi, Cristina; Cavani, Andrea.

In: European Journal of Immunology, Vol. 45, No. 3, 01.03.2015, p. 922-931.

Research output: Contribution to journalArticle

Nardinocchi, Lavinia ; Sonego, Giulio ; Passarelli, Francesca ; Avitabile, Simona ; Scarponi, Claudia ; Failla, Cristina Maria ; Simoni, Stefano ; Albanesi, Cristina ; Cavani, Andrea. / Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. In: European Journal of Immunology. 2015 ; Vol. 45, No. 3. pp. 922-931.
@article{2014547d9c00430ebd7fed23f5a3d99d,
title = "Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer",
abstract = "Interleukin-17 (IL-17) and IL-22 have been reported to play critical roles in autoimmunity and inflammation but information about their role in cancer is limited. In this study, we investigated the role of IL-17 and IL-22 in the progression of human skin basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC). We found that both tumor types are infiltrated with an high number of IL-17+ and IL-22+ T lymphocytes, as demonstrated by immunohistochemistry and by FACS analysis performed on peritumoral T-cell lines isolated from skin biopsies. In vitro studies demonstrated that proliferation and migration of the BCC- and SCC-cell lines M77015 and CAL27 were increased by IL-17 and IL-22. Moreover, IL-17, alone or in combination with TNF-α, was able to induce the production of two cytokines important for tumor progression, IL-6 and IL-8, in CAL27. We also showed that IL-17 upregulated NF-κB signaling, while IL-22 activated the STAT3 pathway and the antiapoptotic AKT protein in M77015 and CAL27. Finally, in vivo experiments demonstrated that IL-17 and IL-22 enhanced tumor growth in nude mice injected with CAL27. Altogether, our findings indicate that high levels of IL-22 and IL-17 in the BCC and SCC microenvironment promote tumor progression.",
keywords = "Cancer, Dermatology, IL-17, IL-22, T cells",
author = "Lavinia Nardinocchi and Giulio Sonego and Francesca Passarelli and Simona Avitabile and Claudia Scarponi and Failla, {Cristina Maria} and Stefano Simoni and Cristina Albanesi and Andrea Cavani",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/eji.201445052",
language = "English",
volume = "45",
pages = "922--931",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "wiley",
number = "3",

}

TY - JOUR

T1 - Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer

AU - Nardinocchi, Lavinia

AU - Sonego, Giulio

AU - Passarelli, Francesca

AU - Avitabile, Simona

AU - Scarponi, Claudia

AU - Failla, Cristina Maria

AU - Simoni, Stefano

AU - Albanesi, Cristina

AU - Cavani, Andrea

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Interleukin-17 (IL-17) and IL-22 have been reported to play critical roles in autoimmunity and inflammation but information about their role in cancer is limited. In this study, we investigated the role of IL-17 and IL-22 in the progression of human skin basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC). We found that both tumor types are infiltrated with an high number of IL-17+ and IL-22+ T lymphocytes, as demonstrated by immunohistochemistry and by FACS analysis performed on peritumoral T-cell lines isolated from skin biopsies. In vitro studies demonstrated that proliferation and migration of the BCC- and SCC-cell lines M77015 and CAL27 were increased by IL-17 and IL-22. Moreover, IL-17, alone or in combination with TNF-α, was able to induce the production of two cytokines important for tumor progression, IL-6 and IL-8, in CAL27. We also showed that IL-17 upregulated NF-κB signaling, while IL-22 activated the STAT3 pathway and the antiapoptotic AKT protein in M77015 and CAL27. Finally, in vivo experiments demonstrated that IL-17 and IL-22 enhanced tumor growth in nude mice injected with CAL27. Altogether, our findings indicate that high levels of IL-22 and IL-17 in the BCC and SCC microenvironment promote tumor progression.

AB - Interleukin-17 (IL-17) and IL-22 have been reported to play critical roles in autoimmunity and inflammation but information about their role in cancer is limited. In this study, we investigated the role of IL-17 and IL-22 in the progression of human skin basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC). We found that both tumor types are infiltrated with an high number of IL-17+ and IL-22+ T lymphocytes, as demonstrated by immunohistochemistry and by FACS analysis performed on peritumoral T-cell lines isolated from skin biopsies. In vitro studies demonstrated that proliferation and migration of the BCC- and SCC-cell lines M77015 and CAL27 were increased by IL-17 and IL-22. Moreover, IL-17, alone or in combination with TNF-α, was able to induce the production of two cytokines important for tumor progression, IL-6 and IL-8, in CAL27. We also showed that IL-17 upregulated NF-κB signaling, while IL-22 activated the STAT3 pathway and the antiapoptotic AKT protein in M77015 and CAL27. Finally, in vivo experiments demonstrated that IL-17 and IL-22 enhanced tumor growth in nude mice injected with CAL27. Altogether, our findings indicate that high levels of IL-22 and IL-17 in the BCC and SCC microenvironment promote tumor progression.

KW - Cancer

KW - Dermatology

KW - IL-17

KW - IL-22

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=84924455824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924455824&partnerID=8YFLogxK

U2 - 10.1002/eji.201445052

DO - 10.1002/eji.201445052

M3 - Article

VL - 45

SP - 922

EP - 931

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 3

ER -